A Novel Osteogenic Activity of Suberoylanilide Hydroxamic Acid is Synergized by BMP-2
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: Many histone deacetylase (HDAC) inhibitors are well recognized as potential anti-cancer drugs. Inhibition of HDACs induces temporal transcription or epigenetic control, thus regulating many different biological responses. Here, we investigated the osteogenic effect of the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA; vorinostat). Methods: The effects of SAHA on osteoblast differentiation were examined in the 6XOSE-Luc reporter assay for determination of runt-related transcription factor 2 (Runx2) activity and alkaline phosphatase (ALP) activity and in an immunoprecipitation assay to determine the Runx2 acetylation state. The osteogenic activity of SAHA in vivo was studied in and receptor activator of nuclear factor-kappa B ligand (RANKL)-induced osteoporotic mouse model. Results: SAHA increased the transcriptional activity of Runx2 in a dose-dependent manner in the 6XOSE-Luc reporter assay. SAHA by itself was unable to induce ALP activity; however, SAHA enhanced ALP activity induced by bone morphogenetic protein-2 (BMP-2). The degree of acetylation of Runx2 was increased with SAHA treatment, which suggests that the increase in Runx2 transcriptional activity might be dependent on stabilization by acetylation. Also, SAHA successfully reversed soluble RA- NKL-induced osteoporotic bone loss. Conclusions: Our study shows an intriguing osteogenic potential of SAHA in a BMP-2-dependent manner and suggests that SAHA could be used at lower doses along with BMP-2 to treat osteoporosis.
Abstract
Background: Many histone deacetylase (HDAC) inhibitors are well recognized as potential anti-cancer drugs. Inhibition of HDACs induces temporal transcription or epigenetic control, thus regulating many different biological responses. Here, we investigated the osteogenic effect of the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA; vorinostat). Methods: The effects of SAHA on osteoblast differentiation were examined in the 6XOSE-Luc reporter assay for determination of runt-related transcription factor 2 (Runx2) activity and alkaline phosphatase (ALP) activity and in an immunoprecipitation assay to determine the Runx2 acetylation state. The osteogenic activity of SAHA in vivo was studied in and receptor activator of nuclear factor-kappa B ligand (RANKL)-induced osteoporotic mouse model. Results: SAHA increased the transcriptional activity of Runx2 in a dose-dependent manner in the 6XOSE-Luc reporter assay. SAHA by itself was unable to induce ALP activity; however, SAHA enhanced ALP activity induced by bone morphogenetic protein-2 (BMP-2). The degree of acetylation of Runx2 was increased with SAHA treatment, which suggests that the increase in Runx2 transcriptional activity might be dependent on stabilization by acetylation. Also, SAHA successfully reversed soluble RA- NKL-induced osteoporotic bone loss. Conclusions: Our study shows an intriguing osteogenic potential of SAHA in a BMP-2-dependent manner and suggests that SAHA could be used at lower doses along with BMP-2 to treat osteoporosis.
참고문헌 (19)
- Rodan GA, "Therapeutic approaches to bone diseases", Science, 289, pp.1508~1514 (2000)
- Eriksen EF, "New developments in the treatment of osteoporosis", Acta Obstet Gynecol Scand, 92, pp.620~636 (2013)
- Bose P, "Histone deacetylase inhibitor(HDACI)mechanisms of action : emerging insights", Pharmacol Ther, 143, pp.323~336 (2014)
- Haberland M, "The many roles of histone deacetylases in development and physiology : implications for disease and therapy", Nat Rev Genet, 10, pp.32~42 (2009)
- Bolden JE, "Anticancer activities of histone deacetylase inhibitors", Nat Rev Drug Discov, 5, pp.769~784 (2006)
- Lin HY, "Targeting histone deacetylase in cancer therapy", Med Res Rev, 26, pp.397~413 (2006)
- Jeon EJ, "Bone morphogenetic protein-2 stimulates Runx2 acetylation", J Biol Chem, 281, pp.16502~16511 (2006)
- McGee-Lawrence ME, "Histone deacetylases in skeletal development and bone mass maintenance", Gene, 474, pp.1~11 (2011)
- Cho HH, "Induction of osteogenic differentiation of human mesenchymal stem cells by histone deacetylase inhibitors", J Cell Biochem, 96, pp.533~542 (2005)
- Lee HW, "Histone deacetylase 1-mediated histone modification regulates osteoblast differentiation", Mol Endocrinol, 20, pp.2432~2443 (2006)
- Kim HN, "Histone deacetylase inhibitor MS-275 stimulates bone formation in part by enhancing Dhx36-mediated TNAP transcription", J Bone Miner Res, 26, pp.2161~2173 (2011)
- Slingerland M, "Histone deacetylase inhibitors : an overview of the clinical studies in solid tumors", Anticancer Drugs, 25, pp.140~149 (2014)
- McGee-Lawrence ME, "Suberoylanilide hydroxamic acid(SAHA ; vorinostat)causes bone loss by inhibiting immature osteoblasts", Bone, 48, pp.1117~1126 (2011)
- Kim HJ, "Establishment and characterization of a stable cell line to evaluate cellular Runx2 activity", J Cell Biochem, 91, pp.1239~1247 (2004)
- Lee JH, "Trolox prevents osteoclastogenesis by suppressing RANKL expression and signaling", J Biol Chem, 284, pp.13725~13734 (2009)
- Long F, "Building strong bones : molecular regulation of the osteoblast lineage", Nat Rev Mol Cell Biol, 13, pp.27~38 (2012)
- Cohen MM Jr., "The new bone biology: pathologic, molecular, and clinical correlates", Am J Med Genet A, 140, pp.2646~2706 (2006)
- Komori T, "Signaling networks in RUNX2-dependent bone development", J Cell Biochem, 112, pp.750~755 (2011)
- Dudakovic A, "Histone deacetylase inhibition promotes osteoblast maturation by altering the histone H4 epigenome and reduces Akt phosphorylation", J Biol Chem, 288, pp.28783~28791 (2013)